Meet Our Team

Meet Our Team2023-11-11T13:47:16+00:00


  • Founder, Product Developer and CEO of BioSafe Technologies, Inc. (women owned) in 2000
  • Founder and CEO of Natureza (women owned) in 2009 to expand its antimicrobial R&D program
  • Majority Owner GML Industries, LLC since 1995

  • 2016 Global Exporter of the Year Award from the Global Chamber, TX

  • 2017 Gold International Stevie Award for Women in Business Female Entrepreneur of the Year
  • 2017 Gold International Stevie Award for Maverick of the Year
  • 2017 Silver International Stevie Award for Lifetime Achievements in Business


  • 16 years as Director of Finance and International Development for Biosafe Technologies, Inc.
  • 9 years as Managing Director of Natureza, Inc.
  • 2 years CEO Italiana Prodotti Minerali (Genoa -Italy)
  • 24 years represented multinational corporations on international trade issues (primarily Washington DC).
GERALD C. COLES MA, PhD, ScD, FSB Chief Scientific Advisor


  • Chief Scientific Advisor
  • MA, Biochemistry,Cambridge
  • PhD Insect Biochemistry
  • ScD based on Selected Research Publications
  • 8 Years Supported by Wellcome Trust
  • 9 years ICI Pharmaceuticals
  • 7 years University of Massachusetts
  • 6 Years Head of Parasitology Department of Central Veterinary Laboratory
  • Senior Research Scientist University of Bristol
  • Author or co-author of 300+ Scientific Publications
TRISTAN COGAN BSc(Hons) PhD. Antimicrobial Projects Manager


  • Antimicrobial Projects Manager
  • Senior Lecturer in Infectious Diseases University of Bristol, UK
  • Dr. Cogan received his undergraduate degree in Biology and PhD in Microbiology at the University of Exeter, UK.
  • 20 Years of experience in the development of anti-infective interventions in human and animal disease.
  • 7 years in public health for the UK Public Health Laboratory Service/Health Protection Agency.
Natureza Research Submitted for Publication in a Peer-Reviewed Journal Sep 2 2022

Natureza Patents New Antibiotic Agents

Natureza Patents New Antibiotic Agents

  • Chitosan-coated carboxylic acids show antimicrobial activity against antibiotic-resistant Gram-negative and positive pathogens.
  • Our novel antibiotic agents show activity against some of the deadliest multi-drug resistant pathogens and there’s NO RESISTANCE.

Antibiotic resistance in bacteria is suggested to be the greatest risk to human health, but new agents are not being brought to market as the rapid evolution of resistance to them means that drug development costs cannot be recouped. Fatty acids have been proposed as a new generation of antibiotics, but toxicity and poor absorption has meant that their use has been impractical in the past.

We have shown that chitosan can be modified to direct fatty acids towards Gram-positive or negative bacteria so that they exert antimicrobial effects and that fatty acids work as effective antibiotics in vitro and in vivo, with

activity against extremely drug resistant pathogens. Bacteria exposed to them do not develop resistance to these agents, and they are not toxic to mammalian cells. Activity was seen against salmonellosis and C. difficile infection in animal models.

Our results demonstrate that fatty acids coated with chitosan are effective antibiotics, and can be used for a long period of time without resistance developing. This suggests that the usage of fatty acids coated in this manner could be sold in sufficient quantities to recoup its development costs, overcoming this barrier. These agents would form a new class of antibiotics, with the novel property of lack of bacterial resistance.

This work is protected by several US and foreign patents and patent applications.

Discover The Future

Discover Natureza® Products.

Go to Top